Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Trastuzumab PET/CT in HER2-Positive Solid Tumors
NCT04757090Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of 89Zr-trastuzumab in HER2-positive solid tumor (HER2+), sponsored by Washington University School of Medicine. Planned start Dec 2021; status: withdrawn.
02
Drugs
89Zr-trastuzumab
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT04757090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757090.